Last 12 months
Inside the activity.
0 purchase rows · 0 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 18, 2020 Filed Aug 20, 2020 22:20 UTC |
Herrmann John A IIIEVP, Chief Legal Officer
|
SaleCommon Stock | 24,594 | $143.92 | $3,539,568.48 |
DisclosureSEC source: 0000904454-20-000588 · edgar.xml · nonDerivative · entry 9 Herrmann John A III · CIK 0001610928 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,923 F1 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $143.30 to $144.29, inclusive. The reporting person undertakes to provide to Novavax, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| August 18, 2020 Filed Aug 20, 2020 22:20 UTC |
Herrmann John A IIIEVP, Chief Legal Officer
|
Exercise / conversionCommon Stock | 8,328 | $46.00 | $383,088.00 |
DisclosureSEC source: 0000904454-20-000588 · edgar.xml · nonDerivative · entry 8 Herrmann John A III · CIK 0001610928 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,517 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 18, 2020 Filed Aug 20, 2020 22:20 UTC |
Herrmann John A IIIEVP, Chief Legal Officer
|
Exercise / conversionCommon Stock | 13,322 | $27.60 | $367,687.20 |
DisclosureSEC source: 0000904454-20-000588 · edgar.xml · nonDerivative · entry 7 Herrmann John A III · CIK 0001610928 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,189 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 18, 2020 Filed Aug 20, 2020 22:20 UTC |
Herrmann John A IIIEVP, Chief Legal Officer
|
Exercise / conversionCommon Stock | 1,952 | $27.00 | $52,704.00 |
DisclosureSEC source: 0000904454-20-000588 · edgar.xml · nonDerivative · entry 6 Herrmann John A III · CIK 0001610928 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,867 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 18, 2020 Filed Aug 20, 2020 22:20 UTC |
Herrmann John A IIIEVP, Chief Legal Officer
|
Exercise / conversionCommon Stock | 393 | $27.00 | $10,611.00 |
DisclosureSEC source: 0000904454-20-000588 · edgar.xml · nonDerivative · entry 5 Herrmann John A III · CIK 0001610928 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,915 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 18, 2020 Filed Aug 20, 2020 22:20 UTC |
Herrmann John A IIIEVP, Chief Legal Officer
|
Exercise / conversionCommon Stock | 11,249 | $99.80 | $1,122,650.20 |
DisclosureSEC source: 0000904454-20-000588 · edgar.xml · nonDerivative · entry 4 Herrmann John A III · CIK 0001610928 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,522 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 18, 2020 Filed Aug 20, 2020 22:20 UTC |
Herrmann John A IIIEVP, Chief Legal Officer
|
Exercise / conversionCommon Stock | 2,499 | $91.00 | $227,409.00 |
DisclosureSEC source: 0000904454-20-000588 · edgar.xml · nonDerivative · entry 3 Herrmann John A III · CIK 0001610928 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,273 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 18, 2020 Filed Aug 20, 2020 22:20 UTC |
Herrmann John A IIIEVP, Chief Legal Officer
|
Exercise / conversionCommon Stock | 7,499 | $36.60 | $274,463.40 |
DisclosureSEC source: 0000904454-20-000588 · edgar.xml · nonDerivative · entry 2 Herrmann John A III · CIK 0001610928 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,774 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 18, 2020 Filed Aug 20, 2020 22:20 UTC |
Herrmann John A IIIEVP, Chief Legal Officer
|
Exercise / conversionCommon Stock | 1,000 | $50.00 | $50,000.00 |
DisclosureSEC source: 0000904454-20-000588 · edgar.xml · nonDerivative · entry 1 Herrmann John A III · CIK 0001610928 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,275 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 18, 2020 Filed Aug 20, 2020 22:14 UTC |
Glenn Gregory MPresident, R&D
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 13,225 | $0.00 Strike: $46.00 | $0.00 |
DisclosureSEC source: 0000904454-20-000586 · edgar.xml · derivative · entry 19 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,524 Underlying: Common Stock · 13,225 shares Expires 2028-12-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F11 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to this option grant vested on the first anniversary of the December 13, 2018 grant date, and the remaining seventy-five percent (75%) of the shares vested or will vest in equal monthly installments over the following three (3) years subject to continued employment through such vesting date. Read SEC document |
| August 18, 2020 Filed Aug 20, 2020 22:14 UTC |
Glenn Gregory MPresident, R&D
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 16,658 | $0.00 Strike: $27.60 | $0.00 |
DisclosureSEC source: 0000904454-20-000586 · edgar.xml · derivative · entry 18 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,341 Underlying: Common Stock · 16,658 shares Expires 2027-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to this option grant vested on the first anniversary of the December 15, 2017 grant date, and the remaining seventy-five percent (75%) of the shares vested or will vest in equal monthly installments over the following three (3) years, subject to continued employment through such vesting date. Read SEC document |
| August 18, 2020 Filed Aug 20, 2020 22:14 UTC |
Glenn Gregory MPresident, R&D
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 2,733 | $0.00 Strike: $27.00 | $0.00 |
DisclosureSEC source: 0000904454-20-000586 · edgar.xml · derivative · entry 17 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,017 Underlying: Common Stock · 2,733 shares Expires 2026-11-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: Vesting of the shares subject to this option grant is subject to the satisfaction of both (1) a time-based vesting requirement, pursuant to which twenty-five percent (25%) of the shares vested on the first anniversary of the November 14, 2016 grant date, and the remaining seventy-five percent (75%) of the shares vested or will vest in equal monthly installments on the first of each month over the following three (3) years, subject to continued employment through such vesting date, and (2) a performance-based vesting requirement, pursuant to which 33.33%, 33.33%, and 33.34% of the shares vested or will vest if, at any time during the four-year period from the November 14, 2016 grant date, the volume-weighted average stock price of the Company's common stock meets or exceeds $80.00, $120.00, or $160.00, respectively, for twenty (20) consecutive trading days. Read SEC document |
| August 18, 2020 Filed Aug 20, 2020 22:14 UTC |
Glenn Gregory MPresident, R&D
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 8,200 | $0.00 Strike: $27.00 | $0.00 |
DisclosureSEC source: 0000904454-20-000586 · edgar.xml · derivative · entry 16 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 550 Underlying: Common Stock · 8,200 shares Expires 2026-11-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to this option grant vested on the first anniversary of the November 14, 2016 grant date, and the remaining seventy-five percent (75%) of the shares vested or will vest in equal monthly installments over the following three (3) years, subject to continued employment through such vesting date. Read SEC document |
| August 18, 2020 Filed Aug 20, 2020 22:14 UTC |
Glenn Gregory MPresident, R&D
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 4,405 | $0.00 Strike: $36.60 | $0.00 |
DisclosureSEC source: 0000904454-20-000586 · edgar.xml · derivative · entry 15 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,405 shares Expires 2023-03-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The shares subject to this option grant vested in four equal annual installments beginning on the first anniversary of the March 2, 2013 grant date. Read SEC document |
| August 18, 2020 Filed Aug 20, 2020 22:14 UTC |
Glenn Gregory MPresident, R&D
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 7,500 | $0.00 Strike: $25.60 | $0.00 |
DisclosureSEC source: 0000904454-20-000586 · edgar.xml · derivative · entry 14 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,500 shares Expires 2022-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The shares subject to this option grant vested in four equal annual installments beginning on the first anniversary of the March 1, 2012 grant date. Read SEC document |
| August 18, 2020 Filed Aug 20, 2020 22:14 UTC |
Glenn Gregory MPresident, R&D
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 3,200 | $0.00 Strike: $50.00 | $0.00 |
DisclosureSEC source: 0000904454-20-000586 · edgar.xml · derivative · entry 13 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,200 shares Expires 2021-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The shares subject to this option grant vested in four equal annual installments beginning on the first anniversary of the March 10, 2011 grant date. Read SEC document |
| August 18, 2020 Filed Aug 20, 2020 22:14 UTC |
Glenn Gregory MPresident, R&D
|
GiftCommon Stock | 1,528 | $0.00 | $0.00 |
DisclosureSEC source: 0000904454-20-000586 · edgar.xml · nonDerivative · entry 12 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 311 Read SEC document |
| August 18, 2020 Filed Aug 20, 2020 22:14 UTC |
Glenn Gregory MPresident, R&D
|
SaleCommon Stock | 525 | $146.58 | $76,954.50 |
DisclosureSEC source: 0000904454-20-000586 · edgar.xml · nonDerivative · entry 11 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,839 F4 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $146.47 to $146.67, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| August 18, 2020 Filed Aug 20, 2020 22:14 UTC |
Glenn Gregory MPresident, R&D
|
SaleCommon Stock | 17,151 | $146.00 | $2,504,046.00 |
DisclosureSEC source: 0000904454-20-000586 · edgar.xml · nonDerivative · entry 10 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,364 F3 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $145.47 to $146.44, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| August 18, 2020 Filed Aug 20, 2020 22:14 UTC |
Glenn Gregory MPresident, R&D
|
SaleCommon Stock | 31,957 | $145.00 | $4,633,765.00 |
DisclosureSEC source: 0000904454-20-000586 · edgar.xml · nonDerivative · entry 9 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,515 F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $144.45 to $145.44, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| August 18, 2020 Filed Aug 20, 2020 22:14 UTC |
Glenn Gregory MPresident, R&D
|
SaleCommon Stock | 6,288 | $143.94 | $905,094.72 |
DisclosureSEC source: 0000904454-20-000586 · edgar.xml · nonDerivative · entry 8 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,472 F1 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $143.45 to $144.43, inclusive. The reporting person undertakes to provide to Novavax, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| August 18, 2020 Filed Aug 20, 2020 22:14 UTC |
Glenn Gregory MPresident, R&D
|
Exercise / conversionCommon Stock | 13,225 | $46.00 | $608,350.00 |
DisclosureSEC source: 0000904454-20-000586 · edgar.xml · nonDerivative · entry 7 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,760 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 18, 2020 Filed Aug 20, 2020 22:14 UTC |
Glenn Gregory MPresident, R&D
|
Exercise / conversionCommon Stock | 16,658 | $27.60 | $459,760.80 |
DisclosureSEC source: 0000904454-20-000586 · edgar.xml · nonDerivative · entry 6 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,535 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 18, 2020 Filed Aug 20, 2020 22:14 UTC |
Glenn Gregory MPresident, R&D
|
Exercise / conversionCommon Stock | 2,733 | $27.00 | $73,791.00 |
DisclosureSEC source: 0000904454-20-000586 · edgar.xml · nonDerivative · entry 5 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,877 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 18, 2020 Filed Aug 20, 2020 22:14 UTC |
Glenn Gregory MPresident, R&D
|
Exercise / conversionCommon Stock | 8,200 | $27.00 | $221,400.00 |
DisclosureSEC source: 0000904454-20-000586 · edgar.xml · nonDerivative · entry 4 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,144 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 18, 2020 Filed Aug 20, 2020 22:14 UTC |
Glenn Gregory MPresident, R&D
|
Exercise / conversionCommon Stock | 4,405 | $36.60 | $161,223.00 |
DisclosureSEC source: 0000904454-20-000586 · edgar.xml · nonDerivative · entry 3 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,944 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 18, 2020 Filed Aug 20, 2020 22:14 UTC |
Glenn Gregory MPresident, R&D
|
Exercise / conversionCommon Stock | 7,500 | $25.60 | $192,000.00 |
DisclosureSEC source: 0000904454-20-000586 · edgar.xml · nonDerivative · entry 2 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,539 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 18, 2020 Filed Aug 20, 2020 22:14 UTC |
Glenn Gregory MPresident, R&D
|
Exercise / conversionCommon Stock | 3,200 | $50.00 | $160,000.00 |
DisclosureSEC source: 0000904454-20-000586 · edgar.xml · nonDerivative · entry 1 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,039 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 18, 2020 Filed Aug 20, 2020 22:09 UTC |
EVANS GARY CDirector
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 4,000 | $0.00 Strike: $27.60 | $0.00 |
DisclosureSEC source: 0000904454-20-000584 · edgar.xml · derivative · entry 10 EVANS GARY C · CIK 0001191410 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,000 shares Expires 2027-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 18, 2020 Filed Aug 20, 2020 22:09 UTC |
EVANS GARY CDirector
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 4,000 | $0.00 Strike: $27.60 | $0.00 |
DisclosureSEC source: 0000904454-20-000584 · edgar.xml · derivative · entry 9 EVANS GARY C · CIK 0001191410 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,000 shares Expires 2027-03-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 18, 2020 Filed Aug 20, 2020 22:09 UTC |
EVANS GARY CDirector
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 1,500 | $0.00 Strike: $36.60 | $0.00 |
DisclosureSEC source: 0000904454-20-000584 · edgar.xml · derivative · entry 8 EVANS GARY C · CIK 0001191410 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,500 shares Expires 2023-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 18, 2020 Filed Aug 20, 2020 22:09 UTC |
EVANS GARY CDirector
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 1,000 | $0.00 Strike: $50.00 | $0.00 |
DisclosureSEC source: 0000904454-20-000584 · edgar.xml · derivative · entry 7 EVANS GARY C · CIK 0001191410 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,000 shares Expires 2021-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 18, 2020 Filed Aug 20, 2020 22:09 UTC |
EVANS GARY CDirector
|
SaleCommon Stock | 10,500 | $150.44 | $1,579,620.00 |
DisclosureSEC source: 0000904454-20-000584 · edgar.xml · nonDerivative · entry 5 EVANS GARY C · CIK 0001191410 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 321,979 F1 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $150.3125 to $151.06, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| August 18, 2020 Filed Aug 20, 2020 22:09 UTC |
EVANS GARY CDirector
|
Exercise / conversionCommon Stock | 4,000 | $27.60 | $110,400.00 |
DisclosureSEC source: 0000904454-20-000584 · edgar.xml · nonDerivative · entry 4 EVANS GARY C · CIK 0001191410 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 332,479 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 18, 2020 Filed Aug 20, 2020 22:09 UTC |
EVANS GARY CDirector
|
Exercise / conversionCommon Stock | 4,000 | $27.60 | $110,400.00 |
DisclosureSEC source: 0000904454-20-000584 · edgar.xml · nonDerivative · entry 3 EVANS GARY C · CIK 0001191410 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 328,479 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 18, 2020 Filed Aug 20, 2020 22:09 UTC |
EVANS GARY CDirector
|
Exercise / conversionCommon Stock | 1,500 | $36.60 | $54,900.00 |
DisclosureSEC source: 0000904454-20-000584 · edgar.xml · nonDerivative · entry 2 EVANS GARY C · CIK 0001191410 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 324,479 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 18, 2020 Filed Aug 20, 2020 22:09 UTC |
EVANS GARY CDirector
|
Exercise / conversionCommon Stock | 1,000 | $50.00 | $50,000.00 |
DisclosureSEC source: 0000904454-20-000584 · edgar.xml · nonDerivative · entry 1 EVANS GARY C · CIK 0001191410 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 322,979 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 25, 2020 Filed Jun 27, 2020 01:20 UTC |
MOTT DAVID MDirector
|
GrantStock Option (Right to buy) · Derivative | 4,400 | $0.00 Strike: $83.54 | $0.00 |
DisclosureSEC source: 0001209191-20-039197 · doc4.xml · derivative · entry 1 MOTT DAVID M · CIK 0001219871 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,400 Underlying: Common Stock · 4,400 shares Expires 2030-06-25 F1 · derivative.exercise_date: One hundred percent (100%) of the shares subject to this option grant under the Novavax, Inc. (the "Company") Amended and Restated 2015 Stock Incentive Plan, as amended, will vest one (1) year from the June 25, 2020 grant date, subject to continued service on the Company's Board of Directors through the vesting date. Read SEC document |
| June 25, 2020 Filed Jun 27, 2020 01:19 UTC |
MCMANUS MICHAEL A JRDirector
|
GrantRestricted Stock Units · Derivative | 3,450 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-039196 · doc4.xml · derivative · entry 2 MCMANUS MICHAEL A JR · CIK 0001051997 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,450 Underlying: Common Stock · 3,450 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Company common stock. F3 · derivative.exercise_date: One hundred percent (100%) of the RSUs subject to this grant under the Plan, will vest one (1) year from the Grant Date, subject to continued service on the Company's Board of Directors through the vesting date. F3 · derivative.expiration_date: One hundred percent (100%) of the RSUs subject to this grant under the Plan, will vest one (1) year from the Grant Date, subject to continued service on the Company's Board of Directors through the vesting date. Read SEC document |
| June 25, 2020 Filed Jun 27, 2020 01:19 UTC |
MCMANUS MICHAEL A JRDirector
|
GrantStock Option (Right to buy) · Derivative | 6,900 | $0.00 Strike: $83.54 | $0.00 |
DisclosureSEC source: 0001209191-20-039196 · doc4.xml · derivative · entry 1 MCMANUS MICHAEL A JR · CIK 0001051997 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,900 Underlying: Common Stock · 6,900 shares Expires 2030-06-25 F1 · derivative.exercise_date: One hundred percent (100%) of the shares subject to this option grant under the Novavax, Inc. (the "Company") Amended and Restated 2015 Stock Incentive Plan, as amended (the "Plan"), will vest one (1) year from the June 25, 2020 grant date (the "Grant Date"), subject to continued service on the Company's Board of Directors through the vesting date. Read SEC document |
| June 25, 2020 Filed Jun 27, 2020 01:18 UTC |
King Rachel K.Director
|
GrantRestricted Stock Units · Derivative | 3,450 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-039195 · doc4.xml · derivative · entry 2 King Rachel K. · CIK 0001589712 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,450 Underlying: Common Stock · 3,450 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Company common stock. F3 · derivative.exercise_date: One hundred percent (100%) of the RSUs subject to this grant under the Plan, will vest one (1) year from the Grant Date, subject to continued service on the Company's Board of Directors through the vesting date. F3 · derivative.expiration_date: One hundred percent (100%) of the RSUs subject to this grant under the Plan, will vest one (1) year from the Grant Date, subject to continued service on the Company's Board of Directors through the vesting date. Read SEC document |
| June 25, 2020 Filed Jun 27, 2020 01:18 UTC |
King Rachel K.Director
|
GrantStock Option (Right to buy) · Derivative | 6,900 | $0.00 Strike: $83.54 | $0.00 |
DisclosureSEC source: 0001209191-20-039195 · doc4.xml · derivative · entry 1 King Rachel K. · CIK 0001589712 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,900 Underlying: Common Stock · 6,900 shares Expires 2030-06-25 F1 · derivative.exercise_date: One hundred percent (100%) of the shares subject to this option grant under the Novavax, Inc. (the "Company") Amended and Restated 2015 Stock Incentive Plan, as amended (the "Plan"), will vest one (1) year from the June 25, 2020 grant date (the "Grant Date"), subject to continued service on the Company's Board of Directors through the vesting date. Read SEC document |
| June 25, 2020 Filed Jun 27, 2020 01:16 UTC |
DOUGLAS RICHARDDirector
|
GrantRestricted Stock Units · Derivative | 3,450 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-039191 · doc4.xml · derivative · entry 2 DOUGLAS RICHARD · CIK 0001021015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,450 Underlying: Common Stock · 3,450 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Company common stock. F3 · derivative.exercise_date: One hundred percent (100%) of the RSUs subject to this grant under the Plan, will vest one (1) year from the Grant Date, subject to continued service on the Company's Board of Directors through the vesting date. F3 · derivative.expiration_date: One hundred percent (100%) of the RSUs subject to this grant under the Plan, will vest one (1) year from the Grant Date, subject to continued service on the Company's Board of Directors through the vesting date. Read SEC document |
| June 25, 2020 Filed Jun 27, 2020 01:16 UTC |
DOUGLAS RICHARDDirector
|
GrantStock Option (Right to buy) · Derivative | 6,900 | $0.00 Strike: $83.54 | $0.00 |
DisclosureSEC source: 0001209191-20-039191 · doc4.xml · derivative · entry 1 DOUGLAS RICHARD · CIK 0001021015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,900 Underlying: Common Stock · 6,900 shares Expires 2030-06-25 F1 · derivative.exercise_date: One hundred percent (100%) of the shares subject to this option grant under the Novavax, Inc. (the "Company") Amended and Restated 2015 Stock Incentive Plan, as amended (the "Plan"), will vest one (1) year from the June 25, 2020 grant date (the "Grant Date"), subject to continued service on the Company's Board of Directors through the vesting date. Read SEC document |
| June 25, 2020 Filed Jun 27, 2020 01:17 UTC |
EVANS GARY CDirector
|
GrantRestricted Stock Units · Derivative | 3,450 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-039193 · doc4.xml · derivative · entry 2 EVANS GARY C · CIK 0001191410 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,450 Underlying: Common Stock · 3,450 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Company common stock. F3 · derivative.exercise_date: One hundred percent (100%) of the RSUs subject to this grant under the Plan, will vest one (1) year from the Grant Date, subject to continued service on the Company's Board of Directors through the vesting date. F3 · derivative.expiration_date: One hundred percent (100%) of the RSUs subject to this grant under the Plan, will vest one (1) year from the Grant Date, subject to continued service on the Company's Board of Directors through the vesting date. Read SEC document |
| June 25, 2020 Filed Jun 27, 2020 01:17 UTC |
EVANS GARY CDirector
|
GrantStock Option (Right to buy) · Derivative | 6,900 | $0.00 Strike: $83.54 | $0.00 |
DisclosureSEC source: 0001209191-20-039193 · doc4.xml · derivative · entry 1 EVANS GARY C · CIK 0001191410 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,900 Underlying: Common Stock · 6,900 shares Expires 2030-06-25 F1 · derivative.exercise_date: One hundred percent (100%) of the shares subject to this option grant under the Novavax, Inc. (the "Company") Amended and Restated 2015 Stock Incentive Plan, as amended (the "Plan"), will vest one (1) year from the June 25, 2020 grant date (the "Grant Date"), subject to continued service on the Company's Board of Directors through the vesting date. Read SEC document |
| June 25, 2020 Filed Jun 27, 2020 01:15 UTC |
YOUNG JAMES FDirector
|
GrantRestricted Stock Units · Derivative | 7,590 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-039190 · doc4.xml · derivative · entry 2 YOUNG JAMES F · CIK 0001219864 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,590 Underlying: Common Stock · 7,590 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Company common stock. F3 · derivative.exercise_date: One hundred percent (100%) of the RSUs subject to this grant under the Plan, will vest one (1) year from the Grant Date, subject to continued service on the Company's Board of Directors through the vesting date. F3 · derivative.expiration_date: One hundred percent (100%) of the RSUs subject to this grant under the Plan, will vest one (1) year from the Grant Date, subject to continued service on the Company's Board of Directors through the vesting date. Read SEC document |
| June 25, 2020 Filed Jun 27, 2020 01:15 UTC |
YOUNG JAMES FDirector
|
GrantStock Option (Right to buy) · Derivative | 15,180 | $0.00 Strike: $83.54 | $0.00 |
DisclosureSEC source: 0001209191-20-039190 · doc4.xml · derivative · entry 1 YOUNG JAMES F · CIK 0001219864 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,180 Underlying: Common Stock · 15,180 shares Expires 2030-06-25 F1 · derivative.exercise_date: One hundred percent (100%) of the shares subject to this option grant under the Novavax, Inc. (the "Company") Amended and Restated 2015 Stock Incentive Plan, as amended (the "Plan"), will vest one (1) year from the June 25, 2020 grant date (the "Grant Date"), subject to continued service on the Company's Board of Directors through the vesting date. Read SEC document |
| June 25, 2020 Filed Jun 30, 2020 01:52 UTC |
Trizzino JohnEVP, CBO and CFO
|
GrantRestricted Stock Units · Derivative | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-078321 · tm2023761-2_4.xml · derivative · entry 1 Trizzino John · CIK 0001468534 · EVP, CBO and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Underlying: Common Stock · 2,500 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock. F2 · derivative.exercise_date: One-third (1/3) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan will vest on each of the first three (3) anniversaries of the June 25, 2020 grant date, subject to continued employment through each such vesting date. F2 · derivative.expiration_date: One-third (1/3) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan will vest on each of the first three (3) anniversaries of the June 25, 2020 grant date, subject to continued employment through each such vesting date. Read SEC document |
| June 25, 2020 Filed Jun 30, 2020 01:51 UTC |
Herrmann John A IIIEVP, Chief Legal Officer
|
GrantRestricted Stock Units · Derivative | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-078318 · tm2023761-1_4.xml · derivative · entry 1 Herrmann John A III · CIK 0001610928 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Underlying: Common Stock · 2,500 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock. F2 · derivative.exercise_date: One-third (1/3) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan will vest on each of the first three (3) anniversaries of the June 25, 2020 grant date, subject to continued employment through each such vesting date. F2 · derivative.expiration_date: One-third (1/3) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan will vest on each of the first three (3) anniversaries of the June 25, 2020 grant date, subject to continued employment through each such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.